Quality of life in pancreatic cancer: Analysis by stage and treatment

被引：81

作者：

Crippa S. ^{[1
]}

Domínguez I. ^{[1
]}

Rodríguez J.R. ^{[1
]}

Razo O. ^{[1
]}

Thayer S.P. ^{[1
]}

Ryan D.P. ^{[2
]}

Warshaw A.L. ^{[1
]}

Fernández-Del Castillo C. ^{[1
]}

机构：

[1] Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114

[2] Department of Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114

来源：

Journal of Gastrointestinal Surgery | 2008年 / 12卷 / 5期

关键词：

Meaningful important difference; Palliation; Pancreatic cancer; Quality of life; Survival;

D O I：

10.1007/s11605-007-0391-9

中图分类号：

学科分类号：

摘要：

In pancreatic cancer patients, survival and palliation of symptoms should be balanced with social and functional impairment, and for this reason, health-related quality of life measurements could play an important role in the decision-making process. The aim of this work was to evaluate the quality of life and survival in 92 patients with different stages of pancreatic adenocarcinoma who underwent surgical and/or medical interventions. Patients were evaluated with the Functional Assessment of Cancer Therapy questionnaires at diagnosis and follow-up (3 and 6 months). At diagnosis, 28 patients (30.5%) had localized disease (group 1) and underwent surgical resection, 34 (37%) had locally advanced (group 2), and 30 (32.5%) metastatic disease (Group 3). Improvement in quality of life was found in group 1, while in group 3, it decreased at follow-up (p = 0.03). No changes in quality of life in group 2 were found. Chemotherapy/chemoradiation seems not to significantly modify quality of life in groups 2 and 3. Median survival time for the entire cohort was 9.8 months (range, 1-24). One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p = 0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life. © 2008 The Society for Surgery of the Alimentary Tract.

引用

页码：783 / 794

页数：11

共 41 条

[1]

Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., Thun M.J., Cancer Statistics, 2005 CA, Cancer J Clin, 55, pp. 10-30, (2005)

[2]

Yeo C.J., Cameron J.L., Lillemoe K.D., Sohn T.A., Campbell K.A., Sauter P.K., Coleman J., Abrams R.A., Hruban R.H., Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity and mortality, Ann Surg, 236, pp. 355-366, (2002)

[3]

Ferrone C.R., Finkelstein D.M., Thayer S.P., Muzikansky A., Fernandez-Del Castillo C., Warshaw A.L., Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma, J Clin Oncol, 24, pp. 2897-2902, (2006)

[4]

Sener S.F., Fremgen A., Menck H.R., Winchester D.P., Pancreatic caner: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the national cancer database, J Am Coll Surg, 189, pp. 1-7, (1999)

[5]

Talamonti M.S., Small W., Mulcahy M.F., Wayne J.D., Attaluri V., Coletti L.M., Zalupski M.M., Hoffman J.P., Freedman G.M., Kinsella T.J., Philip P.A., A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma, Ann Surg Oncol, 13, pp. 150-158, (2006)

[6]

Yip D., Karapetis C., Strickland A., Steer C.B., Goldstein D., Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer, Cochrane Database Syst Rev, 19, (2006)

[7]

Ko A.H., Dito E., Schillinger B., Venook A.P., Bergsland E.K., Tempero M.A., Phase III study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas, J Clin Oncol, 24, pp. 379-385, (2006)

[8]

Lillemoe K.D., Pitt H.A., Palliation. Surgical and otherwise, Cancer, 78, pp. 605-614, (1996)

[9]

Lillemoe K.D., Cameron J.L., Hardacre J.M., Sohn T.A., Sauter P.K., Coleman J., Pitt H.A., Yeo C.J., Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial, Ann Surg, 230, pp. 322-328, (1999)

[10]

Mortenson M.M., Ho H.S., Bold R.J., An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer, Am J Surg, 190, pp. 406-411, (2005)

← 1 2 3 4 5 →